Bregal Sagemount has completed the acquisition of Ennov, an AI-driven technology firm in France focused on healthcare solutions. The transaction was announced on May 12, 2026, and closed on June 30, 2026.
| Acquirer | Bregal Sagemount (US) |
|---|---|
| Target | Ennov (FR) |
| Deal Value | Undisclosed |
| Type of Deal | Buyout |
| Closing Date | 2026-06-30 |
| Advisors (Buy-side) | Bregal Sagemount, Goodwin Procter LLP |
| Advisors (Sell-side) | Ardian, Proskauer Rose LLP |
Deal Mechanics
The acquisition was designed to support Ennov's rapid growth and innovation in artificial intelligence within the healthcare sector. The deal is expected to accelerate Ennov’s global expansion, enhance its product offerings, and position it for future market opportunities.
Strategic Rationale
Bregal Sagemount aims to leverage Ennov's advanced technology to drive operational efficiencies in healthcare organizations globally. The investment will enable Ennov to invest further in research and development of AI technologies that address complex regulatory compliance requirements within the medical industry.
Financial Context
The transaction was subject to regulatory approvals and customary closing conditions. Bregal Sagemount, a growth equity firm with expertise in technology-driven businesses, has deepened its stake in Ennov following previous investments made by Ardian, another prominent private equity firm.
Outlook
Ennov is set to use the proceeds from this investment for strategic initiatives including product development and market expansion. With backing from Bregal Sagemount, Ennov intends to enhance its platform capabilities and solidify its position as a leader in AI solutions for healthcare compliance.